Immunotherapy for triple-negative breast cancer

Yin He; Xiaosheng Wang

doi:10.24294/ti.v6.i2.1793

Immunotherapy for triple-negative breast cancer

Download View pdf

Copyright & License

Trends in Immunotherapy

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI) publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Yin He

Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China.; Cancer Genomics Research Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China; Big Data Research Institute, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China

Xiaosheng Wang

Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China.; Cancer Genomics Research Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China.; Big Data Research Institute, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China.

Home » Trends in Immunotherapy

Immunotherapy for triple-negative breast cancer

Abstract

Keywords

References